Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

A Candida albicans Strain Expressing Mammalian Interleukin-17A Results in Early Control of Fungal Growth during Disseminated Infection.

Huppler AR, Whibley N, Woolford CA, Childs EE, He J, Biswas PS, McGeachy MJ, Mitchell AP, Gaffen SL.

Infect Immun. 2015 Sep;83(9):3684-92. doi: 10.1128/IAI.03057-14. Epub 2015 Jul 6.

2.

Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice.

Huang W, Na L, Fidel PL, Schwarzenberger P.

J Infect Dis. 2004 Aug 1;190(3):624-31. Epub 2004 Jun 22.

PMID:
15243941
3.

IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans.

Kagami S, Rizzo HL, Kurtz SE, Miller LS, Blauvelt A.

J Immunol. 2010 Nov 1;185(9):5453-62. doi: 10.4049/jimmunol.1001153. Epub 2010 Oct 4.

4.

Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice.

Brieland J, Essig D, Jackson C, Frank D, Loebenberg D, Menzel F, Arnold B, DiDomenico B, Hare R.

Infect Immun. 2001 Aug;69(8):5046-55.

5.

CX3CR1 is dispensable for control of mucosal Candida albicans infections in mice and humans.

Break TJ, Jaeger M, Solis NV, Filler SG, Rodriguez CA, Lim JK, Lee CC, Sobel JD, Netea MG, Lionakis MS.

Infect Immun. 2015 Mar;83(3):958-65. doi: 10.1128/IAI.02604-14. Epub 2014 Dec 29.

6.

Pathogenesis of Candida albicans infections in the alternative chorio-allantoic membrane chicken embryo model resembles systemic murine infections.

Jacobsen ID, Grosse K, Berndt A, Hube B.

PLoS One. 2011;6(5):e19741. doi: 10.1371/journal.pone.0019741. Epub 2011 May 13. Erratum in: PLoS One. 2011;6(6). doi:10.1371/annotation/1912450a-b5a7-4dbe-bc2a-cd93579fb0dd.

7.

Antibody blockade of IL-17 family cytokines in immunity to acute murine oral mucosal candidiasis.

Whibley N, Tritto E, Traggiai E, Kolbinger F, Moulin P, Brees D, Coleman BM, Mamo AJ, Garg AV, Jaycox JR, Siebenlist U, Kammüller M, Gaffen SL.

J Leukoc Biol. 2016 Jun;99(6):1153-64. doi: 10.1189/jlb.4A0915-428R. Epub 2016 Jan 4. Erratum in: J Leukoc Biol. 2017 Apr;101(4):1065.

8.

Gastrointestinal colonisation and systemic spread of Candida albicans in mice treated with antibiotics and prednisolone.

Kobayashi-Sakamoto M, Tamai R, Isogai E, Kiyoura Y.

Microb Pathog. 2018 Apr;117:191-199. doi: 10.1016/j.micpath.2018.02.043. Epub 2018 Feb 22.

PMID:
29477742
9.

Differential interaction of the two related fungal species Candida albicans and Candida dubliniensis with human neutrophils.

Svobodová E, Staib P, Losse J, Hennicke F, Barz D, Józsi M.

J Immunol. 2012 Sep 1;189(5):2502-11. doi: 10.4049/jimmunol.1200185. Epub 2012 Jul 30.

10.

Increased IL-17A secretion in response to Candida albicans in autoimmune polyendocrine syndrome type 1 and its animal model.

Ahlgren KM, Moretti S, Lundgren BA, Karlsson I, Ahlin E, Norling A, Hallgren A, Perheentupa J, Gustafsson J, Rorsman F, Crewther PE, Rönnelid J, Bensing S, Scott HS, Kämpe O, Romani L, Lobell A.

Eur J Immunol. 2011 Jan;41(1):235-45. doi: 10.1002/eji.200939883. Epub 2010 Dec 3.

11.

Signaling through IL-17C/IL-17RE is dispensable for immunity to systemic, oral and cutaneous candidiasis.

Conti HR, Whibley N, Coleman BM, Garg AV, Jaycox JR, Gaffen SL.

PLoS One. 2015 Apr 7;10(4):e0122807. doi: 10.1371/journal.pone.0122807. eCollection 2015.

12.

IL-17 plays a central role in initiating experimental Candida albicans infection in mouse corneas.

Zhang H, Li H, Li Y, Zou Y, Dong X, Song W, Jia C, Li S, Xi H, Liu D, Wang Y.

Eur J Immunol. 2013 Oct;43(10):2671-82. doi: 10.1002/eji.201242891. Epub 2013 Aug 12.

13.

Mnn10 Maintains Pathogenicity in Candida albicans by Extending α-1,6-Mannose Backbone to Evade Host Dectin-1 Mediated Antifungal Immunity.

Zhang SQ, Zou Z, Shen H, Shen SS, Miao Q, Huang X, Liu W, Li LP, Chen SM, Yan L, Zhang JD, Zhao JJ, Xu GT, An MM, Jiang YY.

PLoS Pathog. 2016 May 4;12(5):e1005617. doi: 10.1371/journal.ppat.1005617. eCollection 2016 May.

14.

IL-22 defines a novel immune pathway of antifungal resistance.

De Luca A, Zelante T, D'Angelo C, Zagarella S, Fallarino F, Spreca A, Iannitti RG, Bonifazi P, Renauld JC, Bistoni F, Puccetti P, Romani L.

Mucosal Immunol. 2010 Jul;3(4):361-73. doi: 10.1038/mi.2010.22. Epub 2010 May 5.

PMID:
20445503
15.

Protective role of naturally occurring interleukin-17A-producing γδ T cells in the lung at the early stage of systemic candidiasis in mice.

Dejima T, Shibata K, Yamada H, Hara H, Iwakura Y, Naito S, Yoshikai Y.

Infect Immun. 2011 Nov;79(11):4503-10. doi: 10.1128/IAI.05799-11. Epub 2011 Aug 29.

16.

Rheumatoid arthritis patients exhibit impaired Candida albicans-specific Th17 responses.

Bishu S, Su EW, Wilkerson ER, Reckley KA, Jones DM, McGeachy MJ, Gaffen SL, Levesque MC.

Arthritis Res Ther. 2014 Feb 11;16(1):R50. doi: 10.1186/ar4480.

17.

Oral epithelial cells orchestrate innate type 17 responses to Candida albicans through the virulence factor candidalysin.

Verma AH, Richardson JP, Zhou C, Coleman BM, Moyes DL, Ho J, Huppler AR, Ramani K, McGeachy MJ, Mufazalov IA, Waisman A, Kane LP, Biswas PS, Hube B, Naglik JR, Gaffen SL.

Sci Immunol. 2017 Nov 3;2(17). pii: eaam8834. doi: 10.1126/sciimmunol.aam8834.

18.

Early activation of the interleukin-23-17 axis in a murine model of oropharyngeal candidiasis.

Saunus JM, Wagner SA, Matias MA, Hu Y, Zaini ZM, Farah CS.

Mol Oral Microbiol. 2010 Oct;25(5):343-56. doi: 10.1111/j.2041-1014.2010.00570.x.

PMID:
20883223
19.

IL-17-Mediated Immunity to the Opportunistic Fungal Pathogen Candida albicans.

Conti HR, Gaffen SL.

J Immunol. 2015 Aug 1;195(3):780-8. doi: 10.4049/jimmunol.1500909. Review.

20.

TLR-2, IL-10 and IL-17-mediated immunity in experimental chemotherapy murine model of systemic candidiasis; cyclophosphamides' impact and roles.

Dehghan P, Tolouie S, Baradaran B, Nami S, Morovati H.

Microb Pathog. 2018 Jun;119:183-192. doi: 10.1016/j.micpath.2018.04.026. Epub 2018 Apr 17.

PMID:
29673975

Supplemental Content

Support Center